Viking Therapeutics Inc — Cash Flow (NASDAQ:VKTX) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Cash from operating activities -21.78 M-47.59 M-48.4 M-73.38 M-87.79 M-278.69 M -278.69 M Cash from investing activities 41.57 M37.96 M54.75 M-179.09 M-553.37 M341.39 M 341.39 M Cash from financing activities 950 K6.88 M4.16 M271.38 M612.46 M76.44 M 76.44 M Free cash flow -21.78 M-47.59 M-48.4 M-73.38 M-87.79 M-278.69 M -278.69 M

Haberler

Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

Viking Therapeutics, Inc. (VKTX) Surpasses Market Returns: Some Facts Worth Knowing

NVO Crashes 36% in 3 Months: Is This an Indication to Sell the Stock?

LLY Launches GLP-1 Pill, Expands Access Through Pharmacy Partnerships

3 Best Stocks Under $50 to Buy in April 2026, According to Analysts - TipRanks.com

Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound?

WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks

VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug

William Blair, Viking Therapeutic hissesi için tavsiyesini korudu

Morgan Stanley, Viking Therapeutics için hisse tavsiyesini korudu

Viking Therapeutics obezite ilacı denemesinde kayıtları tamamladı